Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
1. A method for inhibiting myostatin activation in a human subject in need thereof, the method comprising a step of administering to the subject a composition comprising an antibody that blocks release of mature myostatin, in an amount effective to cause two or more of the following in the subject:
(a) an increase in mass and/or function of a muscle tissue in the subject;
(b) a decrease in ratio of adipose-to-muscle tissue in the subject;
(c) a decrease in intramuscular fat infiltration in the subject; and
(d) prevention of muscle loss or atrophy in the subject;
wherein the antibody comprises a heavy chain sequence of SEQ ID NO: 50 and a light chain sequence of SEQ ID NO: 51.
2. The method of claim 1 , further comprising a step of selecting the subject who is (i) suffering from a muscle condition or disorder; (ii) suffering from, or at risk of developing, a metabolic disorder; or both (i) and (ii).
3. The method of claim 1 , wherein the subject has a muscle condition selected from the group consisting of: myopathy, muscular atrophy, muscular dystrophy, and nerve injury.
4. The method of claim 3 , wherein the muscular atrophy is associated with spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), or myasthenia gravis.
5. The method of claim 3 , wherein the nerve injury comprises partial denervation of neurons that innervate muscle, or impaired signaling between a motor neuron and a target muscle.
6. The method of claim 1 , wherein the subject has a metabolic disease selected from the group consisting of: type I diabetes, type II diabetes, obesity, metabolic syndrome/prediabetes, cardiovascular disease, non-alcoholic steatohepatitis (NASH), a hypo-metabolic state, double diabetes, Cushing's disease, a metabolic myopathy, androgen deficiency, and an obesity syndrome.
7. The method of claim 6 , wherein the metabolic myopathy is a glycogen storage disease or a lipid storage disorder.
8. The method of claim 1 , wherein the subject is treated with a second therapy.
9. The method of claim 8 , wherein the second therapy comprises a neuroprotective therapy or a stem cell therapy.
10. The method of claim 1 , wherein the amount is an amount of the antibody that causes an increase in a level of circulating latent myostatin in a serum sample, as compared to a control.
11. A method for inhibiting myostatin activation in a human subject having spinal muscular atrophy (SMA), the method comprising a step of administering to the subject a composition comprising an antibody that blocks release of mature myostatin, in an amount effective to
prevent muscle loss or atrophy in the subject;
wherein the antibody comprises a heavy chain sequence of SEQ ID NO: 50 and a light chain sequence of SEQ ID NO: 51.
12. The method of claim 11 , wherein the subject is treated with a second therapy, wherein the second therapy comprises a neuroprotective therapy.
13. The method of claim 11 , wherein the amount is an amount of the antibody that causes an increase in a level of circulating latent myostatin in a serum sample, as compared to a control.
14. A method for inhibiting myostatin activation in a human subject having, or at risk of developing, a metabolic disorder, the method comprising a step of administering to the subject a composition comprising an antibody that blocks release of mature myostatin, in an amount effective to cause two or more of the following in the subject:
(a) an increase in mass and/or function of a muscle tissue in the subject;
(b) a decrease in ratio of adipose-to-muscle tissue in the subject;
(c) a decrease in intramuscular fat infiltration in the subject; and
(d) prevention of muscle loss or atrophy in the subject;
wherein the antibody comprises a heavy chain sequence of SEQ ID NO: 50 and a light chain sequence of SEQ ID NO: 51.
15. The method of claim 14 , wherein the subject has a metabolic disease selected from the group consisting of: type I diabetes, type II diabetes, obesity, metabolic syndrome/prediabetes, cardiovascular disease, non-alcoholic steatohepatitis (NASH), a hypo-metabolic state, double diabetes, Cushing's disease, a metabolic myopathy, androgen deficiency, and an obesity syndrome.
16. The method of claim 15 , wherein the metabolic myopathy is a glycogen storage disease or a lipid storage disorder.
17. The method of claim 14 , wherein the subject has androgen deficiency associated with the metabolic disease.
18. The method of claim 17 , wherein the subject has a cancer.
19. The method of claim 14 , wherein the amount is an amount of the antibody that causes an increase in a level of circulating latent myostatin in a serum sample, as compared to a control.